[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZ685yNS1jg_WTg9iTqplRWsSjjQz3wC5FFNCZzLfoms":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Nathan Kline Institute for Psychiatric Research",[4],23,false,1,1681,0,7,[13,16,19,22,24,26,28,30],{"name":14,"count":15},"Schizophrenia",17,{"name":17,"count":18},"Schizoaffective Disorder",6,{"name":20,"count":21},"Diabetes",2,{"name":23,"count":21},"Cigarette Smoking",{"name":25,"count":8},"Metabolic Syndrome",{"name":27,"count":8},"Hyperglycemia",{"name":29,"count":8},"Cognition",{"name":31,"count":8},"Schizophreniform Disorder",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,78,104,130,156,179,233,263,286,310,339,357,375,400],{"intervention":42,"totalTrials":21,"cells":43},"Varenicline",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":52,"NA":76},{"trials":45,"activeCount":10},[],{"trials":47,"activeCount":10},[],{"trials":49,"activeCount":10},[],{"trials":51,"activeCount":10},[],{"trials":53,"activeCount":10},[54,64],{"nctId":55,"briefTitle":56,"status":57,"phases":58,"primaryCompletion":59,"completion":59,"start":60,"enrollment":61,"conditions":62,"interventions":63},"NCT00802919","Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors","COMPLETED",[38],"2013-12","2008-09",93,[14,23],[42],{"nctId":65,"briefTitle":66,"status":57,"phases":67,"primaryCompletion":68,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":75},"NCT00548470","Varenicline Effects In Schizophrenic Smokers",[38],"2009-09","2010-12","2007-06",14,[14,73,74],"Tobacco Use Disorder","Nicotine Dependance",[42],{"trials":77,"activeCount":10},[],{"intervention":79,"totalTrials":8,"cells":80},"risperidone",{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":89,"NA":102},{"trials":82,"activeCount":10},[],{"trials":84,"activeCount":10},[],{"trials":86,"activeCount":10},[],{"trials":88,"activeCount":10},[],{"trials":90,"activeCount":10},[91],{"nctId":92,"briefTitle":93,"status":57,"phases":94,"completion":95,"start":96,"enrollment":97,"conditions":98,"interventions":99},"NCT00287820","Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism",[38],"2007-09","2004-02",46,[14,20,25,27],[100,101,79],"Olanzapine","olanzapine",{"trials":103,"activeCount":10},[],{"intervention":105,"totalTrials":8,"cells":106},"Pioglitazone",{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":115,"NA":128},{"trials":108,"activeCount":10},[],{"trials":110,"activeCount":10},[],{"trials":112,"activeCount":10},[],{"trials":114,"activeCount":10},[],{"trials":116,"activeCount":10},[117],{"nctId":118,"briefTitle":119,"status":57,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":127},"NCT00231894","Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia",[38],"2010-01","2005-05",56,[20,14,125,126],"Insulin Resistance","Cognitive Impairment",[105],{"trials":129,"activeCount":10},[],{"intervention":131,"totalTrials":8,"cells":132},"Lorazepam",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":154},{"trials":134,"activeCount":10},[],{"trials":136,"activeCount":10},[],{"trials":138,"activeCount":10},[],{"trials":140,"activeCount":10},[],{"trials":142,"activeCount":10},[143],{"nctId":144,"briefTitle":145,"status":57,"phases":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":153},"NCT00044642","Lorazepam-Induced Toxicity in the Aged",[38],"2007-07","2000-12",90,[151,152],"Anxiety Disorders","Generalized Anxiety Disorder",[131],{"trials":155,"activeCount":10},[],{"intervention":157,"totalTrials":8,"cells":158},"Risperidone, divalproex",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":177},{"trials":160,"activeCount":10},[],{"trials":162,"activeCount":10},[],{"trials":164,"activeCount":10},[],{"trials":166,"activeCount":10},[],{"trials":168,"activeCount":10},[169],{"nctId":170,"briefTitle":171,"status":57,"phases":172,"completion":173,"start":174,"enrollment":97,"conditions":175,"interventions":176},"NCT00308360","Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility",[38],"2004-04","1999-09",[14],[157],{"trials":178,"activeCount":10},[],{"intervention":180,"totalTrials":181,"cells":182},"D-serine",4,{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":227,"PHASE4":229,"NA":231},{"trials":184,"activeCount":10},[],{"trials":186,"activeCount":10},[],{"trials":188,"activeCount":10},[189,199,209,218],{"nctId":190,"briefTitle":191,"status":192,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT01474395","N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia","UNKNOWN",[36],"2013-06","2012-03",16,[14,17],[180],{"nctId":200,"briefTitle":201,"status":57,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT00826202","D-serine for the Schizophrenia Prodrome",[36],"2012-11","2009-03",44,[207],"Schizophrenia Prodrome",[180],{"nctId":210,"briefTitle":211,"status":57,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT02156908","D-serine and Cognitive Remediation in Schizophrenia",[36],"2015-12","2014-08",8,[14],[180],{"nctId":219,"briefTitle":220,"status":57,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":226},"NCT00322023","Safety and Effectiveness of D-serine in Schizophrenia",[36],"2009-01","2006-03",55,[14],[180,180,180,180],{"trials":228,"activeCount":10},[],{"trials":230,"activeCount":10},[],{"trials":232,"activeCount":10},[],{"intervention":234,"totalTrials":8,"cells":235},"Betahistine",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":257,"PHASE4":259,"NA":261},{"trials":237,"activeCount":10},[],{"trials":239,"activeCount":10},[],{"trials":241,"activeCount":10},[242],{"nctId":243,"briefTitle":244,"status":57,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":256},"NCT00709202","Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain",[36],"2016-05","2016-12","2008-07",48,[14,17,31,251,252,253,254,255],"Bipolar I Disorder","Bipolar II","Bipolar NOS(Not Otherwise Specified)","Psychotic Disorder Not Otherwise Specified","Autism Spectrum Disorder",[234],{"trials":258,"activeCount":10},[],{"trials":260,"activeCount":10},[],{"trials":262,"activeCount":10},[],{"intervention":264,"totalTrials":8,"cells":265},"D Serine",{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":267,"activeCount":10},[],{"trials":269,"activeCount":10},[],{"trials":271,"activeCount":10},[272],{"nctId":273,"briefTitle":274,"status":57,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":196,"conditions":278,"interventions":279},"NCT00817336","Biomarkers in Schizophrenia",[36],"2011-07","2009-06",[14,17],[264],{"trials":281,"activeCount":10},[],{"trials":283,"activeCount":10},[],{"trials":285,"activeCount":10},[],{"intervention":287,"totalTrials":8,"cells":288},"Sodium Oxybate",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":290,"activeCount":10},[],{"trials":292,"activeCount":10},[],{"trials":294,"activeCount":10},[295],{"nctId":296,"briefTitle":297,"status":57,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":215,"conditions":301,"interventions":303},"NCT00594256","Sodium Oxybate in Schizophrenia With Insomnia",[36],"2009-04","2008-05",[14,302],"Insomnia Related to Schizophrenia (307.42)",[287],{"trials":305,"activeCount":10},[],{"trials":307,"activeCount":10},[],{"trials":309,"activeCount":10},[],{"intervention":100,"totalTrials":21,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":326},{"trials":313,"activeCount":10},[],{"trials":315,"activeCount":10},[],{"trials":317,"activeCount":10},[],{"trials":319,"activeCount":10},[],{"trials":321,"activeCount":10},[322],{"nctId":92,"briefTitle":93,"status":57,"phases":323,"completion":95,"start":96,"enrollment":97,"conditions":324,"interventions":325},[38],[14,20,25,27],[100,101,79],{"trials":327,"activeCount":10},[328],{"nctId":329,"briefTitle":330,"status":57,"phases":331,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":336},"NCT01123408","Clozapine and Olanzapine Treatment of Aggression",[39],"2004-07","1999-06",110,[14],[337,100,338],"Clozapine","Haloperidol",{"intervention":337,"totalTrials":8,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":351},{"trials":342,"activeCount":10},[],{"trials":344,"activeCount":10},[],{"trials":346,"activeCount":10},[],{"trials":348,"activeCount":10},[],{"trials":350,"activeCount":10},[],{"trials":352,"activeCount":10},[353],{"nctId":329,"briefTitle":330,"status":57,"phases":354,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":355,"interventions":356},[39],[14],[337,100,338],{"intervention":338,"totalTrials":8,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":360,"activeCount":10},[],{"trials":362,"activeCount":10},[],{"trials":364,"activeCount":10},[],{"trials":366,"activeCount":10},[],{"trials":368,"activeCount":10},[],{"trials":370,"activeCount":10},[371],{"nctId":329,"briefTitle":330,"status":57,"phases":372,"primaryCompletion":332,"completion":332,"start":333,"enrollment":334,"conditions":373,"interventions":374},[39],[14],[337,100,338],{"intervention":376,"totalTrials":8,"cells":377},"glycine",{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":379,"activeCount":10},[],{"trials":381,"activeCount":10},[],{"trials":383,"activeCount":10},[],{"trials":385,"activeCount":10},[],{"trials":387,"activeCount":10},[],{"trials":389,"activeCount":10},[390],{"nctId":391,"briefTitle":392,"status":57,"phases":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT00405535","Adjunctive Glycine for Obsessive Compulsive Disorder",[39],"2006-12","2004-06",24,[398],"Obsessive Compulsive Disorder",[376],{"intervention":401,"totalTrials":8,"cells":402},"Metformin",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":404,"activeCount":10},[],{"trials":406,"activeCount":10},[],{"trials":408,"activeCount":10},[],{"trials":410,"activeCount":10},[],{"trials":412,"activeCount":10},[],{"trials":414,"activeCount":10},[415],{"nctId":416,"briefTitle":417,"status":418,"phases":419,"primaryCompletion":420,"completion":420,"start":300,"enrollment":421,"conditions":422,"interventions":424},"NCT01177709","Metformin for Weight Loss in Schizophrenia","TERMINATED",[39],"2011-04",12,[14,423],"Obesity",[401]]